Breakthrough in Oncology: mRNA Cancer Vaccine Tested in Russia

The Gamaleya National Research Center for Epidemiology and Microbiology has produced the first three test batches of its mRNA cancer vaccine, according to the center’s director, Alexander Gintsburg.

Photo: Generated by AI (DALL·E 3 by OpenAI) is licensed under Free for commercial use (OpenAI License)

Cancer cure

"Funds were allocated to construct a factory for producing mRNA vaccines at the Gamaleya Institute. The factory has not only been built but is fully equipped and has released the first three validation batches. Most importantly, at our leading oncology center, the Hertsen Center, under the guidance of academician Andrey Kaprin, we have obtained the complete regulatory package for using the technology — from diagnostics to mRNA production and patient administration," said Gintsburg during a conference at the V. P. Ivannikov Institute for System Programming of the Russian Academy of Sciences, TASS reports.

Earlier, the Russian Ministry of Health approved the use of two anti-cancer therapies: a therapeutic mRNA vaccine and a peptide-based vaccine. The personalized mRNA vaccine for melanoma therapy, named "Neooncovac," is produced by the National Medical Research Center of Radiology of the Ministry of Health and was developed in collaboration with the Gamaleya Institute and the National Medical Research Center of Oncology named after Blokhin.

The vaccine is intended for adult patients with inoperable or metastatic melanoma, providing a new option in personalized cancer therapy.